Annual EBITDA
-$33.25 M
-$9.99 M-42.95%
July 31, 2024
Summary
- As of February 26, 2025, BCTX annual EBITDA is -$33.25 million, with the most recent change of -$9.99 million (-42.95%) on July 31, 2024.
- During the last 3 years, BCTX annual EBITDA has fallen by -$19.52 million (-142.28%).
- BCTX annual EBITDA is now -386483.72% below its all-time high of -$8600.00, reached on July 31, 2006.
Performance
BCTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$5.13 M
+$569.30 K+10.00%
October 31, 2024
Summary
- As of February 26, 2025, BCTX quarterly EBITDA is -$5.13 million, with the most recent change of +$569.30 thousand (+10.00%) on October 31, 2024.
- Over the past year, BCTX quarterly EBITDA has stayed the same.
- BCTX quarterly EBITDA is now -145.92% below its all-time high of $11.16 million, reached on January 31, 2022.
Performance
BCTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$29.87 M
+$3.37 M+10.15%
October 31, 2024
Summary
- As of February 26, 2025, BCTX TTM EBITDA is -$29.87 million, with the most recent change of +$3.37 million (+10.15%) on October 31, 2024.
- Over the past year, BCTX TTM EBITDA has stayed the same.
- BCTX TTM EBITDA is now -2102.76% below its all-time high of $1.49 million, reached on April 30, 2021.
Performance
BCTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BCTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.0% | 0.0% | 0.0% |
| 3 y3 years | -142.3% | 0.0% | 0.0% |
| 5 y5 years | -611.6% | 0.0% | 0.0% |
BCTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -142.3% | at low | -145.9% | +48.8% | -536.5% | +29.8% |
| 5 y | 5-year | -735.4% | at low | -145.9% | +81.4% | -2102.8% | +29.8% |
| alltime | all time | <-9999.0% | at low | -145.9% | +81.4% | -2102.8% | +29.8% |
BriaCell Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$5.13 M(-10.0%) | -$29.87 M(-10.1%) |
| Jul 2024 | -$33.25 M(+43.0%) | -$5.70 M(-38.3%) | -$33.25 M(-5.7%) |
| Apr 2024 | - | -$9.23 M(-6.1%) | -$35.25 M(+11.2%) |
| Jan 2024 | - | -$9.83 M(+15.6%) | -$31.70 M(+20.3%) |
| Oct 2023 | - | -$8.50 M(+10.4%) | -$26.36 M(+13.3%) |
| Jul 2023 | -$23.26 M(-13.3%) | -$7.70 M(+35.8%) | -$23.26 M(+45.3%) |
| Apr 2023 | - | -$5.67 M(+26.6%) | -$16.00 M(-21.3%) |
| Jan 2023 | - | -$4.48 M(-17.0%) | -$20.34 M(+333.4%) |
| Oct 2022 | - | -$5.40 M(+1109.2%) | -$4.69 M(-82.5%) |
| Jul 2022 | -$26.82 M(+95.5%) | -$446.50 K(-95.5%) | -$26.82 M(-36.9%) |
| Apr 2022 | - | -$10.01 M(-189.7%) | -$42.53 M(+44.2%) |
| Jan 2022 | - | $11.16 M(-140.6%) | -$29.50 M(-27.8%) |
| Oct 2021 | - | -$27.53 M(+70.5%) | -$40.85 M(+197.7%) |
| Jul 2021 | -$13.72 M(+244.8%) | -$16.15 M(-635.5%) | -$13.72 M(-1020.0%) |
| Apr 2021 | - | $3.02 M(-1718.8%) | $1.49 M(-173.8%) |
| Jan 2021 | - | -$186.30 K(-53.6%) | -$2.02 M(-37.9%) |
| Oct 2020 | - | -$401.80 K(-57.1%) | -$3.25 M(-20.6%) |
| Jul 2020 | -$3.98 M(-14.8%) | -$936.20 K(+88.0%) | -$4.10 M(-15.0%) |
| Apr 2020 | - | -$498.00 K(-64.9%) | -$4.82 M(-11.5%) |
| Jan 2020 | - | -$1.42 M(+13.9%) | -$5.45 M(+4.3%) |
| Oct 2019 | - | -$1.25 M(-24.9%) | -$5.22 M(+10.0%) |
| Jul 2019 | -$4.67 M(+13.2%) | -$1.66 M(+47.4%) | -$4.75 M(-2.1%) |
| Apr 2019 | - | -$1.13 M(-5.7%) | -$4.85 M(+0.3%) |
| Jan 2019 | - | -$1.19 M(+54.7%) | -$4.84 M(+9.2%) |
| Oct 2018 | - | -$771.80 K(-56.1%) | -$4.43 M(+6.5%) |
| Jul 2018 | -$4.13 M(+59.7%) | -$1.76 M(+58.3%) | -$4.16 M(+19.5%) |
| Apr 2018 | - | -$1.11 M(+41.2%) | -$3.48 M(+7.8%) |
| Jan 2018 | - | -$787.30 K(+57.6%) | -$3.23 M(+16.2%) |
| Oct 2017 | - | -$499.60 K(-53.8%) | -$2.78 M(+6.7%) |
| Jul 2017 | -$2.58 M(+55.2%) | -$1.08 M(+25.7%) | -$2.60 M(+50.7%) |
| Apr 2017 | - | -$859.30 K(+154.3%) | -$1.73 M(+51.5%) |
| Jan 2017 | - | -$337.90 K(+4.0%) | -$1.14 M(-27.7%) |
| Oct 2016 | - | -$324.80 K(+58.3%) | -$1.58 M(+0.8%) |
| Jul 2016 | -$1.67 M(-38.9%) | -$205.20 K(-24.7%) | -$1.56 M(+5.0%) |
| Apr 2016 | - | -$272.50 K(-64.8%) | -$1.49 M(-7.1%) |
| Jan 2016 | - | -$775.10 K(+148.3%) | -$1.60 M(-44.1%) |
| Oct 2015 | - | -$312.20 K(+138.3%) | -$2.87 M(+9.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jul 2015 | -$2.73 M(+525.2%) | -$131.00 K(-66.1%) | -$2.61 M(-1.6%) |
| Apr 2015 | - | -$386.00 K(-81.1%) | -$2.65 M(+12.1%) |
| Jan 2015 | - | -$2.04 M(+3607.5%) | -$2.37 M(+474.4%) |
| Oct 2014 | - | -$55.00 K(-68.5%) | -$412.30 K(-5.9%) |
| Jul 2014 | -$436.20 K(+2.9%) | -$174.50 K(+74.8%) | -$438.10 K(+23.1%) |
| Apr 2014 | - | -$99.80 K(+20.2%) | -$355.80 K(-5.1%) |
| Jan 2014 | - | -$83.00 K(+2.7%) | -$374.80 K(-6.4%) |
| Oct 2013 | - | -$80.80 K(-12.4%) | -$400.60 K(-6.0%) |
| Jul 2013 | -$423.90 K(-22.9%) | -$92.20 K(-22.4%) | -$426.10 K(-8.0%) |
| Apr 2013 | - | -$118.80 K(+9.2%) | -$463.00 K(-1.4%) |
| Jan 2013 | - | -$108.80 K(+2.4%) | -$469.50 K(-6.5%) |
| Oct 2012 | - | -$106.30 K(-17.7%) | -$502.00 K(-7.9%) |
| Jul 2012 | -$550.10 K(-47.6%) | -$129.10 K(+3.0%) | -$545.10 K(-40.8%) |
| Apr 2012 | - | -$125.30 K(-11.3%) | -$921.00 K(-10.6%) |
| Jan 2012 | - | -$141.30 K(-5.4%) | -$1.03 M(-4.0%) |
| Oct 2011 | - | -$149.40 K(-70.4%) | -$1.07 M(+4.1%) |
| Jul 2011 | -$1.05 M(+225.0%) | -$505.00 K(+115.3%) | -$1.03 M(+82.0%) |
| Apr 2011 | - | -$234.60 K(+27.3%) | -$566.50 K(+13.6%) |
| Jan 2011 | - | -$184.30 K(+71.9%) | -$498.50 K(+36.2%) |
| Oct 2010 | - | -$107.20 K(+165.3%) | -$366.00 K(+15.9%) |
| Jul 2010 | -$323.30 K(+38.3%) | -$40.40 K(-75.8%) | -$315.70 K(-24.0%) |
| Apr 2010 | - | -$166.60 K(+221.6%) | -$415.60 K(+61.1%) |
| Jan 2010 | - | -$51.80 K(-9.0%) | -$257.90 K(+7.4%) |
| Oct 2009 | - | -$56.90 K(-59.4%) | -$240.20 K(+2.0%) |
| Jul 2009 | -$233.70 K(+104.8%) | -$140.30 K(+1476.4%) | -$235.50 K(+55.0%) |
| Apr 2009 | - | -$8900.00(-73.9%) | -$151.90 K(-11.3%) |
| Jan 2009 | - | -$34.10 K(-34.7%) | -$171.30 K(+9.3%) |
| Oct 2008 | - | -$52.20 K(-7.9%) | -$156.70 K(+36.5%) |
| Jul 2008 | -$114.10 K(-11.6%) | -$56.70 K(+100.4%) | -$114.80 K(+17.7%) |
| Apr 2008 | - | -$28.30 K(+45.1%) | -$97.50 K(+18.6%) |
| Jan 2008 | - | -$19.50 K(+89.3%) | -$82.20 K(-23.6%) |
| Oct 2007 | - | -$10.30 K(-73.9%) | -$107.60 K(-14.5%) |
| Jul 2007 | -$129.10 K(+1401.2%) | -$39.40 K(+203.1%) | -$125.80 K(+45.6%) |
| Apr 2007 | - | -$13.00 K(-71.0%) | -$86.40 K(+17.7%) |
| Jan 2007 | - | -$44.90 K(+57.5%) | -$73.40 K(+157.5%) |
| Oct 2006 | - | -$28.50 K | -$28.50 K |
| Jul 2006 | -$8600.00 | - | - |
FAQ
- What is BriaCell Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for BriaCell Therapeutics?
- What is BriaCell Therapeutics annual EBITDA year-on-year change?
- What is BriaCell Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for BriaCell Therapeutics?
- What is BriaCell Therapeutics quarterly EBITDA year-on-year change?
- What is BriaCell Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for BriaCell Therapeutics?
- What is BriaCell Therapeutics TTM EBITDA year-on-year change?
What is BriaCell Therapeutics annual EBITDA?
The current annual EBITDA of BCTX is -$33.25 M
What is the all time high annual EBITDA for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual EBITDA is -$8600.00
What is BriaCell Therapeutics annual EBITDA year-on-year change?
Over the past year, BCTX annual EBITDA has changed by -$9.99 M (-42.95%)
What is BriaCell Therapeutics quarterly EBITDA?
The current quarterly EBITDA of BCTX is -$5.13 M
What is the all time high quarterly EBITDA for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly EBITDA is $11.16 M
What is BriaCell Therapeutics quarterly EBITDA year-on-year change?
Over the past year, BCTX quarterly EBITDA has changed by $0.00 (0.00%)
What is BriaCell Therapeutics TTM EBITDA?
The current TTM EBITDA of BCTX is -$29.87 M
What is the all time high TTM EBITDA for BriaCell Therapeutics?
BriaCell Therapeutics all-time high TTM EBITDA is $1.49 M
What is BriaCell Therapeutics TTM EBITDA year-on-year change?
Over the past year, BCTX TTM EBITDA has changed by $0.00 (0.00%)